APA (7th ed.) Citation

Oya, K., Nakamura, Y., Watanabe, R., Tanaka, R., Ichimura, Y., Kubota, N., . . . Fujisawa, Y. (2023, December). Eribulin mesylate exerts antitumor effects via CD103. OncoImmunology.

Chicago Style (17th ed.) Citation

Oya, Kazumasa, et al. "Eribulin Mesylate Exerts Antitumor Effects via CD103." OncoImmunology Dec. 2023.

MLA (9th ed.) Citation

Oya, Kazumasa, et al. "Eribulin Mesylate Exerts Antitumor Effects via CD103." OncoImmunology, Dec. 2023.

Warning: These citations may not always be 100% accurate.